Normal
Awards & grants

ImmuPharma has received the following awards:

  • 2015: Lupuzor founder Dr Sylviane Muller
    Dr Sylviane Muller recently awarded Medal of Innovation from CNRS for work on both Lupuzor's mechanism of action and its applicability to other autoimmune conditions (some having orphan drug status). Click here for full announcement
    CNRS/Dr Slyviane Muller video link
  • ImmuPharma was the winner of The New Economy's  Healthcare Awards 2012, being voted "best Medical Research & Development Company - Europe. Click here for the article.
  • “Best Drug Development Company, Europe” at The New Economy Pharmaceutical & Healthcare Awards 2010.
  • “Breakthrough of the Year 2009” European Mediscience Award - sponsored by Piper Jaffray - in association with the BIA.
  • “Best Technology 2009” at the AIM Awards - sponsored by PricewaterhouseCoopers LLP.
 
ImmuPharma has also been awarded financial grants for developing its novel drug candidates, the most recent being:
  • In 2014 the French region of Aquitaine (around Bordeaux) awarded ImmuPharma’s subsidiary Ureka a non-refundable grant of approx. €400,000 EUR to develop Ureka’s Urelix technology. The Urelix technology is a way to mimic natural peptides having a helical conformation with artificial residues in order to strengthen this conformation and protect it from enzymatic degradation.
 
 

Dr Sylviane Muller recently awarded Medal of Innovation from CNRS

ImmuPharma was the winner of The New Economy's Healthcare Awards 2012